Characteristics of human malignant glioma are excessive proliferation, infiltrative growth, angiogenesis and suppression of anti‐tumor immune surveillance. Transforming growth factor‐beta (TGF‐β), a versatile cytokine, is intimately involved in the regulation of these processes. Here, we discuss the interactions of TGF‐β with growth factors, such as basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) and platelet derived growth factor (PDGF), metalloproteinases (MMP‐2, MMP‐9) and their inhibitor, plasmin activator inhibitor‐1 (PAI‐1), and immune cells, like natural killer cells, T‐cells and microglia. The differential effects of TGF‐β in glioma biology are outlined with emphasis on the induction of a survival advantage for glioma cells by enforced cell growth, migration, invasion, angiogenesis and immune paralysis. By virtue of its growth regulatory and immunomodulatory properties, TGF‐β promises to become a novel target for the experimental therapy of human malignant glioma. Microsc. Res. Tech. 52:401–410, 2001. © 2001 Wiley‐Liss, Inc.